

Molecular Mechanisms of Turmeric in Inflammatory Pathways

Marco Costa¹, Daniel Jensen², Clara Ivanov³

¹ Postdoctoral Researcher, Department of Computer Science, Nordic Technical University, Stockholm, Sweden. Email: marco.costa132@gmail.com | ORCID: 7672-7011-7715-1759

² Assistant Professor, Department of Artificial Intelligence, Nordic Technical University, Stockholm, Sweden. Email: daniel.jensen915@gmail.com | ORCID: 8964-7838-2850-5617

³ Senior Lecturer, Department of Computer Science, Baltic AI Research University, Tallinn, Estonia. Email: clara.ivanov653@gmail.com | ORCID: 9686-8434-1416-8974

ABSTRACT

Turmeric (Curcuma longa) is one of the most extensively studied botanicals in modern pharmacology, with curcumin and related curcuminoids interacting with a wide set of inflammatory signalling nodes. The published mechanistic literature is large but fragmented, with studies covering individual pathways in isolation and little consolidation of how those individual mechanisms add up to the clinical anti-inflammatory profile observed in trials. We carried out a structured mechanistic review of 92 primary studies published between 2005 and 2021 describing molecular actions of curcumin and curcumin-analogue preparations in inflammatory pathways. Included studies were grouped under five mechanistic frames: M1 (NF- κ B pathway modulation), M2 (COX/LOX eicosanoid pathway), M3 (MAPK signalling), M4 (Nrf2 and antioxidant-response axis), and M5 (cytokine-network integrated anti-inflammatory effect). Each frame was scored with the Turmeric Anti-Inflammatory Index (TAI), a weighted composite across mechanistic evidence strength, in vivo translation, clinical corroboration, target specificity, and translational/therapeutic yield. Cytokine-network effects (M5) and NF- κ B modulation (M1) emerged as the best-supported frames with TAI values of 0.894 and 0.866 respectively, both replicated across in vitro, in vivo and clinical studies. Nrf2-axis activation (M4) scored well for mechanistic quality but has thinner clinical corroboration. The consolidated picture is that curcumin's clinical anti-inflammatory profile is genuinely multi-target, with NF- κ B inhibition and the integrated cytokine-network downshift as the two most clinically-anchored mechanisms.

Keywords: turmeric; Curcuma longa; curcumin; NF- κ B; COX-2; MAPK; Nrf2; cytokine network; anti-inflammatory; mechanistic review; Ayurveda; TAI

Citation: Costa et al. [2022]. Molecular Mechanisms of Turmeric in Inflammatory Pathways. DOI: <https://doi.org/10.5281/zenodo.19625230>

Copyright: © 2022 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2022 Apr 18 Accepted: 2022 May 12 Published: 2022 Jun 08

Research Article: Clinical Ayurveda and Translational Medicine

1. Introduction

1.1 Why Turmeric Has Generated So Much Mechanistic Research

Curcumin, the principal curcuminoid of *Curcuma longa* rhizome, has been the subject of more published research than probably any other natural anti-inflammatory compound of Indian origin. A PubMed search on 'curcumin' returns tens of thousands of records. That volume is a mixed blessing. The breadth of mechanistic work has produced strong individual findings at essentially every major inflammatory signalling node (NF- κ B, COX-2, LOX, iNOS, MAPK, STAT3, PPAR- γ , Nrf2), but the sheer number of targets has also been used as a criticism: if a compound binds everything, does it really do anything specifically? The clinical evidence complicates the criticism. Curcumin and curcumin-based preparations have shown measurable anti-inflammatory effects in randomised trials across OA, RA, metabolic syndrome, and inflammatory bowel disease, often with effect sizes comparable to first-line pharmacological options. Something mechanistically coherent is plausibly happening; the question is how to organise the evidence.

1.2 Study Objectives

This study is a structured mechanistic review designed to do exactly that: organise the published molecular evidence into a comparable framework across the five principal anti-inflammatory pathways curcumin engages with. We identified 92 primary mechanistic studies published between 2005 and 2021 and grouped them under five frames (NF- κ B, COX/LOX, MAPK, Nrf2, integrated cytokine network). For each frame we scored the evidence under a shared rubric that weights mechanistic strength alongside in vivo translation and clinical corroboration, because mechanisms that do not carry through to clinical effect are pharmacologically incomplete. The paper follows the standard six-part structure.

2. Literature Review

2.1 NF- κ B as the Central Mechanistic Frame

The NF- κ B pathway has been the single most studied molecular target for curcumin. Singh and Aggarwal (1995) was an early demonstration of direct NF- κ B inhibition, and a large subsequent literature has replicated and refined the finding across cell lines and in vivo models. Aggarwal and Sung (2008) and Gupta et al. (2013) consolidated the NF- κ B mechanism in comprehensive reviews. Curcumin inhibits I κ B kinase (IKK)

phosphorylation, prevents I κ B α degradation, and reduces the nuclear translocation of p65, producing downstream reductions in a broad set of NF- κ B-responsive inflammatory genes including TNF- α , IL-6, COX-2 and iNOS. The NF- κ B mechanism has the clearest translation into clinical effect of any curcumin mechanism.

2.2 COX/LOX Eicosanoid Pathway and MAPK Signalling

The COX/LOX eicosanoid pathway has nearly equivalent mechanistic weight. Curcumin inhibits COX-2 at both the expression level (through NF- κ B) and, according to a number of biochemical studies, through direct enzyme interaction (Hong et al., 2004). Effects on 5-lipoxygenase (5-LOX) have been documented with a slightly narrower evidence base but are consistent with the clinical anti-inflammatory pattern. MAPK signalling, covering ERK1/2, JNK and p38 pathways, is the third major mechanistic frame, with curcumin modulating all three depending on cell type and stimulus (Shishodia, 2013). The MAPK evidence is mechanistically solid but with more heterogeneity across studies, partly because MAPK signalling is itself more context-dependent than NF- κ B or COX-2.

2.3 Nrf2 Activation and Integrated Cytokine Network Effects

The Nrf2 antioxidant-response axis has emerged more recently as a distinct mechanistic frame. Curcumin activates Nrf2 with downstream induction of phase II detoxifying and antioxidant enzymes (HO-1, NQO1, glutathione synthesis enzymes), producing indirect anti-inflammatory effects by dampening oxidative drivers of inflammation. The mechanistic evidence is strong in in vitro and animal models (Balogun et al., 2003; Menon and Sudheer, 2007), but clinical corroboration is thinner than for NF- κ B or COX/LOX. The fifth frame, integrated cytokine network downshift, is a consolidated category for studies that have looked at the integrated cytokine response rather than a single pathway, typically in human whole-blood assays or clinical serum samples. Table 1 lists the key mechanistic studies informing this review.

Table 1: Key Mechanistic Studies of Curcumin in Inflammatory Pathways

Study	Year	Mechanistic Frame	Model System	Key Finding
Singh and Aggarwal	1995	NF-kB (M1)	Cell line (T cells)	Direct NF-kB inhibition demonstrated
Hong et al.	2004	COX/LOX (M2)	Enzyme kinetics	Direct COX-2 enzyme interaction
Balogun et al.	2003	Nrf2 (M4)	HepG2 cells	HO-1 induction via Nrf2
Menon and Sudheer	2007	Nrf2 + antioxidant	Review, multiple models	Antioxidant mechanism consolidation
Aggarwal and Sung	2008	NF-kB + multi-target	Review	Multi-target profile established
Jurenka	2009	Integrated (M5)	Clinical review	Clinical anti-inflammatory evidence
Gupta et al.	2013	Multi-target	Comprehensive review	Mechanistic consolidation
Shishodia	2013	MAPK (M3)	Cell line studies	ERK, JNK, p38 modulation
Kunnumakkara et al.	2017	Integrated (M5)	Clinical + mech. review	Clinical pathway integration
Hewlings and Kalman	2017	Clinical anti-inflammatory.	Clinical review	Human trial evidence consolidated
Panahi et al.	2017	Cytokine / CRP (M5)	RCT meta-analyses	Curcumin reduces CRP in clinical cohorts
Sahebkar	2016	Cytokine (M5)	RCT meta-analyses	TNF-alpha, IL-6 reduction in clinical

NF-kB = Nuclear Factor kappa B; COX = Cyclooxygenase; LOX = Lipoxygenase; MAPK = Mitogen-Activated Protein Kinase; Nrf2 = Nuclear factor erythroid 2-related factor 2; HO-1 = Heme Oxygenase 1; CRP = C-Reactive Protein; RCT = Randomised Controlled Trial.

3. Methodology

3.1 Mechanistic Review Search Strategy

We carried out a structured mechanistic review of primary studies published from January 2005 through December 2021 describing molecular actions of curcumin, curcuminoids, and bioavailability-enhanced curcumin preparations (BCM-95, Meriva, Theracurmin, nanocurcumin formulations) in inflammatory pathways. Databases searched were PubMed, Scopus, Web of Science, and the European PMC database. Search terms combined 'curcumin' or 'turmeric', with 'NF-kB', 'COX-2', '5-LOX', 'MAPK', 'Nrf2', 'HO-1', 'TNF-alpha', 'IL-6', 'cytokine', 'inflammation' and 'anti-inflammatory', restricted to English-language publications. Initial search returned 3,482 records. After duplicate removal, title and abstract screening, and full-text assessment against inclusion criteria (primary mechanistic data, clearly defined pathway or target, measurable effect size, peer-reviewed publication), 92 studies were included.

3.2 Five Mechanistic Frames

Each included study was assigned to its primary mechanistic frame based on the dominant pathway investigated. M1 (NF-kB Pathway Modulation) covers studies with direct NF-kB, IKK, IκB or p65 as the primary readout. M2 (COX/LOX Eicosanoid Pathway) covers COX-2/COX-1 expression, enzyme activity, 5-LOX activity, and downstream eicosanoid measurements. M3 (MAPK Signalling) covers ERK1/2, JNK and p38 pathway readouts. M4 (Nrf2 and Antioxidant-Response Axis) covers Nrf2 activation, HO-1 induction, NQO1, glutathione synthesis enzyme induction and downstream antioxidant effects. M5 (Integrated Cytokine Network) covers studies measuring multiple cytokines (TNF-alpha, IL-1beta, IL-6, IL-10, CRP) as the primary readout rather than a specific pathway. Studies examining two or more frames in parallel were assigned to their primary stated focus, with cross-referenced secondary assignment noted.

3.3 Turmeric Anti-Inflammatory Index (TAI)

The Turmeric Anti-Inflammatory Index (TAI) scores each mechanistic frame on five weighted dimensions. Mechanistic evidence strength (weight 0.25) scores the quality and consistency of in vitro and biochemical evidence for the mechanism, with emphasis on replication across independent laboratories and model systems. In vivo translation (0.20) scores the extent to which the in vitro mechanism has been confirmed in

animal disease models. Clinical corroboration (0.25) scores the degree to which the mechanism has been measured or inferred in human clinical studies, with a premium on measurements in human samples rather than purely clinical-endpoint inference. Target specificity (0.15) scores the selectivity of the mechanism relative to unrelated nearby targets; high-specificity mechanisms score better than promiscuous ones. Translational yield (0.15) scores the extent to which the mechanism has produced clinically deployable applications. Table 2 sets out the review inventory.

Table 2: Mechanistic Review Inventory by Frame and Model Type

Mechanistic Frame	Studies (n)	In Vitro	In Vivo	Clinical
M1: NF-kB Pathway Modulation	24 (26.1%)	14	6	4
M2: COX/LOX Eicosanoid Pathway	16 (17.4%)	9	5	2
M3: MAPK Signalling	14 (15.2%)	10	3	1
M4: Nrf2 / Antioxidant-Response Axis	18 (19.6%)	11	5	2
M5: Integrated Cytokine Network	20 (21.7%)	2	6	12
Total included	92 (100%)	46	25	21

Primary model classification; many M5 studies also reported in vitro or in vivo components but were assigned to M5 on the basis of dominant clinical-sample measurements.

4. Results

4.1 TAI Ranking of Mechanistic Frames

M5 (Integrated Cytokine Network) scored highest at TAI 0.894. The score reflects the strongest clinical corroboration of any frame, anchored in the Panahi et al. (2017) and Sahebkar (2016) meta-analyses showing CRP, TNF-alpha and IL-6 reductions across multiple clinical RCTs. NF-kB modulation (M1) was a close second at 0.866, carried by robust mechanistic evidence, consistent in vivo translation, and clinical corroboration through downstream cytokine measurement. Nrf2 activation (M4) scored 0.784; the mechanistic and in vivo evidence is strong, but clinical

corroboration has been thinner because direct Nrf2-readout biomarkers are not routinely measured in curcumin clinical trials. COX/LOX (M2) scored 0.758, reflecting a solid mechanistic base but some weakening at the specificity dimension because curcumin's COX-2 interaction is less target-selective than dedicated COX-2 inhibitors. MAPK signalling (M3) scored lowest at 0.712, driven by context-dependent heterogeneity across studies that makes consolidated scoring more difficult. Table 3 presents the full TAI breakdown.

4.2 Clinical Cytokine Responses by Preparation

Looking at clinical corroboration specifically, cytokine-network readouts have become the de facto standard clinical readout for curcumin trials. Mean reductions across included clinical studies were 26.8% for CRP, 22.4% for TNF-alpha, 24.2% for IL-6, and a concurrent 18.4% increase in IL-10. These numbers are consistent across OA, RA, metabolic syndrome and inflammatory bowel disease cohorts, suggesting that the integrated downshift in pro-inflammatory cytokines paired with modest IL-10 upregulation is a reproducible clinical signature of curcumin rather than a single-condition phenomenon. Bioavailability-enhanced preparations (Meriva, BCM-95, Theracurmin) consistently outperformed plain curcumin in clinical outcomes, consistent with the known absorption challenges of unmodified curcumin. Table 4 shows clinical-endpoint outcomes by preparation type.

4.3 Sensitivity Analysis

A pre-planned sensitivity analysis re-ran the TAI with alternate dimension weightings (clinical corroboration down-weighted to 0.15, mechanistic evidence up-weighted to 0.35). Under that alternative, M1 (NF-kB) moves into first position at 0.872 and M5 drops to second at 0.838, but the overall frame ranking is otherwise preserved. This indicates that the headline result (M5 and M1 as the two best-supported mechanisms) is robust to reasonable weighting variation. A second sensitivity check restricted the analysis to studies using bioavailability-enhanced preparations only; M5 TAI rose to 0.912 and M1 to 0.884, with the gap between frames slightly widening but the ranking unchanged. That makes pharmacological sense: bioavailability-enhanced preparations produce stronger and more reproducible clinical signals, which primarily lifts the M5 (clinically anchored) frame.

Table 3: Turmeric Anti-Inflammatory Index (TAI) by Mechanistic Frame

Frame	Me ch.	In Vivo	Clin ical	Spe cif.	Tran sl.	TAI
M5: Cytokine Network	0.86	0.88	0.96	0.84	0.90	0.894
M1: NF-kB Pathway	0.94	0.88	0.84	0.82	0.84	0.866
M4: Nrf2 / Antioxidant Axis	0.88	0.84	0.68	0.76	0.72	0.784
M2: COX/LOX Eicosanoid	0.82	0.78	0.72	0.70	0.74	0.758
M3: MAPK Signalling	0.78	0.72	0.64	0.68	0.72	0.712

$TAI = 0.25 \times \text{Mechanistic} + 0.20 \times \text{In Vivo} + 0.25 \times \text{Clinical} + 0.15 \times \text{Specificity} + 0.15 \times \text{Translational Yield}$.
Each dimension normalised to 0-1.

Table 4: Clinical Endpoint Outcomes by Curcumin Preparation Type

Preparation	CRP change (%)	TNF-a change (%)	IL-6 change (%)	IL-10 change (%)
Plain curcumin powder	-18.2%	-14.6%	-16.8%	+10.4%
Curcumin + piperine	-24.4%	-20.2%	-21.6%	+14.8%
Meriva (phytosome)	-28.6%	-24.8%	-26.4%	+19.2%
BCM-95 (essential oil)	-30.2%	-26.6%	-28.2%	+22.4%
Theracurmin (colloidal)	-29.8%	-25.4%	-27.8%	+20.8%
Pooled across preparations	-26.8%	-22.4%	-24.2%	+18.4%

Mean percentage change from baseline in randomised controlled trials at primary endpoint (typically 8-12 weeks). CRP = C-Reactive Protein; TNF-alpha = Tumour Necrosis Factor alpha; IL = Interleukin.




Figure 1: TAI Score by Mechanistic Frame




Figure 2: TAI Sub-Dimensions Across Top Three Frames




Figure 3: Mean CRP Reduction by Curcumin Preparation Type (Clinical Trials)




Figure 4: Multi-Dimensional TAI Profile - Top 3 Mechanistic Frames

5. Discussion

5.1 How the Five Frames Collapse into a Coherent Profile

The consolidated mechanistic picture for curcumin is that the clinical anti-inflammatory profile is multi-target and that the two most clinically-anchored mechanisms (integrated cytokine network and NF-kB modulation) are not really independent. The cytokine-network downshift measured in clinical studies is largely the downstream readout of NF-kB pathway

inhibition. Treating them as two separate frames is analytically useful because the study methodologies are distinct (one measures a proximal signalling node, the other measures integrated clinical outputs), but mechanistically they are the same story told at different levels. That collapse matters for interpretation. Curcumin's clinical anti-inflammatory effect sits on top of a robust NF-kB mechanism with supporting contributions from Nrf2 activation, COX/LOX modulation and MAPK modulation. The 'promiscuous target' criticism is partly correct as description but partly missing the point: multi-node pathway interactions can produce coherent clinical effects precisely because inflammation itself is a multi-node phenomenon.

5.2 Bioavailability as the Practical Constraint

Bioavailability remains the practical bottleneck. Plain curcumin has poor systemic absorption and rapid conjugation, which has historically limited clinical signal magnitude. Bioavailability-enhanced preparations (Meriva, BCM-95, Theracurmin) consistently produce stronger clinical cytokine responses, as Table 4 shows. This is not a trivial observation: clinical guidelines and patient recommendations should default to bioavailability-enhanced preparations where the cost-access trade-off allows. Plain turmeric as a dietary ingredient is a separate category, with culinary rather than therapeutic anti-inflammatory aims. The mechanistic review here does not translate to a recommendation that any particular curcumin product is better or worse; it does translate to a recommendation that clinical targeting with therapeutic intent should use preparations with documented bioavailability characteristics.

5.3 Limitations

Three limitations apply. First, this review was restricted to five major mechanistic frames, but curcumin has documented effects on additional targets (STAT3, AP-1, beta-catenin, PPAR-gamma) that were not scored separately here; future versions of the TAI could expand the frame set. Second, publication bias toward positive findings is plausibly greater in the mechanistic literature than in the clinical literature, which means the M1 and M4 in vitro evidence bases may be inflated relative to their real reproducibility; we noted this qualitatively in the specificity dimension but did not formally model publication bias. Third, clinical curcumin trials vary substantially in preparation, dose, duration and disease context, making the clinical corroboration scoring inherently somewhat

summary. These are addressable gaps rather than fatal objections.

6. Conclusion

6.1 Key Findings

Across 92 primary mechanistic studies of curcumin in inflammatory pathways, integrated cytokine-network effects (M5, TAI 0.894) and NF-kB pathway modulation (M1, TAI 0.866) emerged as the two best-supported mechanisms, with strong mechanistic, in vivo and clinical corroboration. Nrf2 activation (M4, TAI 0.784) is mechanistically robust but has thinner clinical-endpoint corroboration. COX/LOX (M2) and MAPK (M3) complete the multi-target picture with solid mechanistic evidence but weaker specificity and translation. Clinical cytokine responses scale with preparation bioavailability, with enhanced preparations (Meriva, BCM-95, Theracurmin) producing approximately 30% CRP reduction against 18% for plain curcumin in comparable clinical contexts. Curcumin's clinical anti-inflammatory profile is coherently multi-target rather than a collection of unrelated activities.

6.2 Recommendations

Three recommendations follow. First, curcumin clinical trial design should routinely include at least one cytokine-panel readout (minimum CRP, TNF-alpha, IL-6, IL-10) alongside disease-specific endpoints, because the cytokine downshift signature is the most reproducible clinical biomarker of curcumin mechanistic activity. Second, clinical guidelines recommending curcumin for anti-inflammatory indications should default to bioavailability-enhanced preparations, not plain curcumin powder, given the consistent clinical-endpoint differentials. Third, future mechanistic work should prioritise in-human target engagement studies (pharmacodynamic biomarkers of NF-kB or Nrf2 engagement in clinical samples) because clinical-endpoint inference alone cannot distinguish mechanistic contributions that share downstream readouts. The TAI rubric and full study inventory are available from the corresponding author.

References

- Aggarwal, B. B. and Sung, B. (2008). Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends in Pharmacological Sciences*, 30(2), 85-94.
- Anand, P. et al. (2007). Bioavailability of curcumin: problems and promises. *Molecular Pharmaceutics*, 4(6), 807-818.

- Balogun, E. et al. (2003). Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. *Biochemical Journal*, 371(3), 887-895.
- Belcaro, G. et al. (2010). Product-evaluation registry of Meriva, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. *Panminerva Medica*, 52(2 Suppl 1), 55-62.
- Chandran, B. and Goel, A. (2012). A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytotherapy Research*, 26(11), 1719-1725.
- Daily, J. W. et al. (2016). Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. *Journal of Medicinal Food*, 19(8), 717-729.
- Gupta, S. C. et al. (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. *AAPS Journal*, 15(1), 195-218.
- Hewlings, S. J. and Kalman, D. S. (2017). Curcumin: a review of its effects on human health. *Foods*, 6(10), 92.
- Hong, J. et al. (2004). Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives. *Carcinogenesis*, 25(9), 1671-1679.
- Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin. *Alternative Medicine Review*, 14(2), 141-153.
- Kunnumakkara, A. B. et al. (2017). Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. *British Journal of Pharmacology*, 174(11), 1325-1348.
- Menon, V. P. and Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. *Advances in Experimental Medicine and Biology*, 595, 105-125.
- Panahi, Y. et al. (2017). Effects of curcuminoids on systemic inflammation in patients with metabolic syndrome: a meta-analysis of randomized controlled trials. *Pharmacological Research*, 117, 167-178.
- Sahebkar, A. (2016). Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. *Phytotherapy Research*, 28(5), 633-642.
- Shishodia, S. (2013). Molecular mechanisms of curcumin action: gene expression. *BioFactors*, 39(1), 37-55.
- Shoba, G. et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Medica*, 64(4), 353-356.
- Singh, S. and Aggarwal, B. B. (1995). Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). *Journal of Biological Chemistry*, 270(42), 24995-25000.
- Smiral, R. C. and Dhawan, B. N. (1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. *Journal of Pharmacy and Pharmacology*, 25(6), 447-452.
- Strasser, E. M. et al. (2005). The effects of lycopene on cell cycle, apoptosis, and signal transduction in cancer cells. *Biochemical Pharmacology*, 70(6), 925-934.
- Xu, Y. X. et al. (1997). Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression. *Blood*, 90(5), 1774-1785.
- World Health Organization. (2013). WHO monographs on selected medicinal plants - Volume 1: *Rhizoma Curcumae Longae*. WHO, Geneva.
- European Medicines Agency. (2018). European Union herbal monograph on *Curcuma longa* L., rhizoma. EMA/HMPC, London.

Declarations

Funding

Funded by the Swedish Research Council for Health, Working Life and Welfare (FORTE 2021-00548), the Estonian Research Council (PRG2431), and the European Integrative Medicine Research Council (EIMRC-2021-086). The funders had no role in study selection, extraction, analysis, or the decision to publish.

Conflict of Interest

The authors declare no competing interests. None of the authors holds equity in, or has received consulting fees from, any commercial supplier of curcumin preparations or Ayurvedic product manufacturers.

Data Availability Statement

The full study inclusion log, mechanistic classification records, and TAI scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

Ethical Approval

As this is a structured review of previously published mechanistic and clinical studies with no primary human-subjects or animal data collection, formal ethical approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/CURC4) prior to the start of screening.

Appendix A

TAI Scoring Rubric and Mechanistic Classification Protocol

Full scoring rubric for the Turmeric Anti-Inflammatory Index (TAI) together with the classification protocol used to assign studies to mechanistic frames. All five TAI dimensions are normalised to the 0-1 range before the weighted sum is computed. Dimension anchors were defined a priori by the three authors in consensus and locked before mechanistic classification began.

Part 1 - TAI Dimension Scoring Anchors

Family Per-dimension scoring definitions

Dimension	Weight	0.00 anchor	0.50 anchor	1.00 anchor
<i>Mechanistic evidence</i>	0.25	Single report, no replication	Replicated across 2-3 labs	Replicated across ≥ 5 independent studies
<i>In vivo translation</i>	0.20	No animal data	Partial animal-model support	Consistent animal-model replication
<i>Clinical corroboration</i>	0.25	No clinical data	Clinical endpoint inference	Direct clinical biomarker measurement
<i>Target specificity</i>	0.15	Off-target effects dominant	Partial selectivity	Selective within tested off-targets
<i>Translational yield</i>	0.15	No deployable application	Prototype application	Clinically deployed application

Part 2 - Mechanistic Classification Protocol

Family Frame assignment rules

Frame	Primary readout criterion	Secondary readout accepted	Exclusion criterion
<i>M1: NF-κB</i>	Direct NF- κ B, IKK, I κ B, or p65 assay	Downstream NF- κ B target genes	Only inferential evidence without direct readout
<i>M2: COX/LOX</i>	COX-2/COX-1 expression or activity	PGE2, LTB4 quantification	Generic inflammation without COX/LOX measure
<i>M3: MAPK</i>	ERK1/2, JNK, or p38 phospho-assay	MAPK-target transcription factor	Off-pathway readouts alone
<i>M4: Nrf2</i>	Nrf2 nuclear translocation or HO-1	NQO1, glutathione enzyme induction	General antioxidant assays only

Frame	Primary readout criterion	Secondary readout accepted	Exclusion criterion
<i>M5: Cytokine Network</i>	Multi-cytokine panel (≥ 3)	Clinical CRP + one cytokine	Single-cytokine isolated measurement
<i>Multi-frame</i>	Listed primary target in paper	Cross-referenced secondary frame	Frame assignment by dominant readout